Intellia Therapeutics, Inc. (NTLA)
Healthcare
- Fundamental
- 3
- Sentiment
- 4
- Technical
- 4
Bullish momentum breakout: place a GTC buy stop at 15.56 to clear the 15.49-15.55 resistance band, use 14.34 as the ATR-based protective stop, and target 18.00 then 19.83. Do not chase at market after the catalyst spike.
Company overview
Intellia Therapeutics, Inc. is a biotechnology company focused on developing therapeutic treatments using genome editing. It is advancing several in vivo programs, including NTLA-2001 for transthyretin amyloidosis and NTLA-2002 for hereditary angioedema. The company also has an ex vivo pipeline and collaborates with various partners to develop genomic medicines.
Fundamental
fairIntellia is a speculative biotech with strong liquidity but deeply negative profitability and cash flow.
Intellia is a clinical-stage gene-editing biotech with solid near-term liquidity (10-Q reports $517.2M cash/cash equivalents/marketable securities and >12 months runway) and improving clinical momentum (Phase 3 HAELO results for lonvo-z plus a rolling BLA targeting an early-2027 launch). Fundamentals remain weak because profitability and cash generation are deeply negative (FY2025 net margin ~-609.85%, TTM free-cash-flow yield ~-21.72%), and discounted-cash-flow outputs are negative. Overall: well-funded but high-uncertainty clinical bet rather than a cash-flow compounding story (fundamentalScore 3/5).
Sentiment
goodRecent positive Phase 3 results have sparked interest, but broader sentiment remains mixed with some dilution concerns.
A fresh, company-announced bullish catalyst (2026-06-13 additional positive Phase 3 HAELO results for lonvoguran ziclumeran/lonvo-z in hereditary angioedema) is still in the ≤14d digestion window. Media tone is mildly positive but cooler than the very bullish 30–90d baseline around the pivotal Phase 3/BLA headlines; legal/regulatory scans show no regulator-confirmed investigations (Red-Flag Screen clean).
Technical
goodThe stock has reclaimed key moving averages, suggesting a potential breakout above resistance.
NTLA closed at 14.92 after a catalyst-driven upside expansion, reclaiming SMA20/50/200 and finishing above daily VWAP. Volume and ADX confirm the move, while RSI is supportive and MACD has crossed above its signal line; the lagging caution is that EMA9 still sits slightly below EMA21 and MACD remains just below zero. That mix supports a bullish breakout trigger above nearby resistance rather than a market buy into a stretched day-one spike.
You’re looking at 2026-06-15 — about 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.